These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 30630241)
1. [Expert Consensus on Short-Course Therapy of Multi-drug Resistant Tuberculosis]. ; Zhonghua Jie He He Hu Xi Za Zhi; 2019 Jan; 42(1):5-8. PubMed ID: 30630241 [TBL] [Abstract][Full Text] [Related]
2. Challenges and Outlooks in Multi-drug Resistant Tuberculosis. Caminero Luna JA Arch Bronconeumol; 2017 Aug; 53(8):417-418. PubMed ID: 28314633 [No Abstract] [Full Text] [Related]
3. [Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment]. Chinese Society of Tuberculosis of Chinese Medical Association Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):733-749. PubMed ID: 31594107 [TBL] [Abstract][Full Text] [Related]
4. [Clofazimine in treatment of multi-drug resistant tuberculosis]. Jing W; Wang QF; Chu NH Zhonghua Jie He He Hu Xi Za Zhi; 2016 May; 39(5):396-9. PubMed ID: 27180598 [No Abstract] [Full Text] [Related]
12. How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform? Gebhard A; van den Hof S; Cobelens F Am J Respir Crit Care Med; 2015 Jul; 192(1):117. PubMed ID: 26131997 [No Abstract] [Full Text] [Related]
13. Efficacy and safety of regimens for drug-resistant tuberculosis. Yates TA; Nunn AJ Lancet Infect Dis; 2016 Nov; 16(11):1218-1219. PubMed ID: 27788973 [No Abstract] [Full Text] [Related]
14. Emerging resistant clone of Mycobacterium tuberculosis in west Asia. Mokrousov I Lancet Infect Dis; 2016 Dec; 16(12):1326-1327. PubMed ID: 27998587 [No Abstract] [Full Text] [Related]
15. Pakistan's battle with multi-drug resistant tuberculosis--establishing the ground rules. Saleem T; Khalid U J Pak Med Assoc; 2012 Jan; 62(1):80. PubMed ID: 22352115 [No Abstract] [Full Text] [Related]
16. Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform? Bastard M; Bonnet M; du Cros P; Khamraev AK; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F Am J Respir Crit Care Med; 2015 Jul; 192(1):117-8. PubMed ID: 26131996 [No Abstract] [Full Text] [Related]
17. Resistant plus susceptible tuberculosis: the undiscovered country. Ahmad Khan F; Behr M J Infect Dis; 2014 Jun; 209(11):1682-4. PubMed ID: 24523512 [No Abstract] [Full Text] [Related]
18. Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan. Chien JY; Lai CC; Tan CK; Yu CJ; Hsueh PR Clin Infect Dis; 2013 Apr; 56(7):1054-5. PubMed ID: 23175554 [No Abstract] [Full Text] [Related]
19. Rapid emergence of Veziris N; Bernard C; Guglielmetti L; Le Du D; Marigot-Outtandy D; Jaspard M; Caumes E; Lerat I; Rioux C; Yazdanpanah Y; Tiotiu A; Lemaitre N; Brossier F; Jarlier V; Robert J; Sougakoff W; Aubry A; ; Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182568 [No Abstract] [Full Text] [Related]
20. A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers. Schito M; Dolinger DL EBioMedicine; 2015 Oct; 2(10):1262-5. PubMed ID: 26629499 [No Abstract] [Full Text] [Related] [Next] [New Search]